
CryoPort (CYRX) Stock Forecast & Price Target
CryoPort (CYRX) Analyst Ratings
Bulls say
CryoPort is a unique company that is well-positioned to benefit from the growing demand for cell and gene therapies. Their strong financial performance and expanding market share in the Life Sciences Services segment demonstrate their strong competitive position in the market. The company's investment in facilities and expansion into new markets, such as China, demonstrate their commitment to continued growth and innovation. With a strong management team and a positive outlook for the future, I am bullish on CryoPort's stock and believe it has the potential for significant upside in the coming years.
Bears say
CryoPort is currently overvalued and trading above its five-year range of 1.9-5.2x EV/Revenue. The company has seen strong growth in its Life Sciences Services segment, but its Life Sciences Products segment has experienced slow growth due to a tough comp. Despite potential upside in the year, the fundamental reasons for a negative outlook on the stock include its current valuation and potential for future competition in the market.
This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.
CryoPort (CYRX) Analyst Forecast & Price Prediction
Start investing in CryoPort (CYRX)
Order type
Buy in
Order amount
Est. shares
0 shares